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Abstract
Background: Using a knock-out mouse model, it was shown that NETO1 is a critical component of the NMDAR complex,
and that loss of Neto1 leads to impaired hippocampal long term potentiation and hippocampal-dependent learning and
memory. Moreover, hemizygosity of NETO1 was shown to be associated with autistic-like behavior in humans.
Purpose of the Research: We examined the association between schizophrenia and the neuropilin and tolloid-like 1 gene
(NETO1). First, we selected eight single nucleotide polymorphisms (SNPs) within the NETO1 locus, based on the Japanese
schizophrenia genome wide association study (JGWAS) results and previously conducted association studies. These SNPs
were genotyped in the replication sample comprised of 963 schizophrenic patients and 919 healthy controls. We also
examined the effect of associated SNPs on scores in the Continuous Performance Test and the Wisconsin Card Sorting Test
Keio version (schizophrenic patients 107, healthy controls 104).
Results: There were no significant allele-wise and haplotype-wise associations in the replication analysis after Bonferroni
correction. However, in meta-analysis (JGWAS and replication dataset) three association signals were observed (rs17795324:
p=0.028, rs8098760: p=0.017, rs17086492: p=0.003). These SNPs were followed up but we could not detect the allele-
specific effect on cognitive performance measured by the Continuous performance test (CPT) and Wisconsin Card Sorting
test (WCST).
Major Conclusions: We did not detect evidence for the association of NETO1 with schizophrenia in the Japanese
population. Common variants within the NETO1 locus may not increase the genetic risk for schizophrenia in the Japanese
population. Additionally, common variants investigated in the current study did not affect cognitive performance, as
measured by the CPT and WCST.
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Introduction
Theglutamate hypothesisofschizophrenia(GHS)emergedinthe
early 1980 s as an alternative to the prevailing theory of altered
dopamine neurotransmission. The GHS is based on the observation
that non-competitive antagonists of the N-methyl-d-asparate
(NMDA) subtype of glutamate receptors, such as phencyclidine
(PCP), ketamine and MK-801, induce a psychotic reaction in
healthy individuals that resembles schizophrenia (both the positive
and negative symptoms). When the same compounds are
administered to patients with schizophrenia, exacerbation of
psychotic symptoms can be the outcome [1]. Together, these
observations suggest that diminished function of the NMDA
receptor (NMDAR) may play a role in the pathoetiology of
schizophrenia. Moreover, evidence from morphological, clinical
and neuroimaging studies have provided support for the GHS by
mapping cognitive impairment, alterations in blood flow and
changesinneuronalmorphologytoparticularbrainareas,including
the frontal and cingulate cortices, both of which are areas with
extensive excitatory glutamatergic neurotransmission [2].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28929The N-methyl-D-aspartate receptor (NMDAR), a major
excitatory ligand-gated ion channel in the central nervous system,
is composed of a heterotetramer between two NR1 and two NR2
subunits. Moreover, the NMDAR is a principal mediator of
synaptic plasticity [3]. It has been shown that corticolimbic
NMDAR hypofunction is one of the core molecular mechanisms
relevant for phenotypes observed in animal models of schizophre-
nia [4]. One of the genes that regulate NMDAR function is
neuropilin and tolloid-like 1 gene (NETO1). NETO1 maps to the
18q22-q23 and three alternative splicing variants (mRNA level)
have been observed [5]. Specifically, variants 1 and 2 are detected
in the retina while variant 3 is specific for fetal and adult brain.
NETO1 is a transmembrane protein, which has two extracellular
CUB domains, a low-density lipoprotein class A (LDLa) domain, a
transmembrane domain and classical type I PDZ-domain binding
motif [5] (Figure 1). Deletion of Neto1 leads to deficits in synaptic
plasticity in mice while stimulation of the AMPA receptor can
partially compensate for deficits caused by Neto1 deletion [6].
NETO1 interacts with the core NMDAR subunits, NR2A and
NR2B and a scaffolding protein, postsynaptic density-95 (PSD-95),
maintaining the abundance of NR2A-containing NMDARs in the
postsynaptic density of the hippocampus. PSD-95 is a protein that
is almost exclusively located in the postsynaptic density of neurons,
and is important in anchoring synaptic proteins [7]. Increase in
surface NR2A, but not NR2B, occurs in hippocampal neurons
derived from dysbindin-null mutant mice (Dys-/-). Dysbindin
controls hippocampal LTP by selective regulation of the surface
expression of NR2A [8]. In situ hybridization studies of
schizophrenia detected decreased transcript expression of the
NR1 subunit, increased transcript expression of the NR2B subunit
and unchanged transcript expression of the NR2A subunit in
hippocampus [9]. Therefore, regulation of NR2 in hippocampus
in schizophrenia may be relevant for the etiology of schizophrenia
and NETO1 may play an important role in the molecular
mechanism by maintaining the abundance of NR2A-containing
NMDARs in the postsynaptic density of hippocampal neurons.
Moreover, NETO1 interacts with kainate receptors (KAR), one of
the glutamate receptors, in mouse brain. NETO1 modulates the
KAR affinity for the endogenous ligand glutamate. NETO1
modulates not only kinetics, but also the amplitude of slow
excitatory postsynaptic current in KAR (KAR-EPSC) [10,11].
NETO1 fundamentally alters the function and neuronal localiza-
tion of GluK1-containing KAR [10,11]. Therefore, NETO1 may
influence glutamate neurotransmission through modulation of
KAR and NMDAR properties.
Genetic studies suggested that the NETO1 locus could harbor
genetic variants that are relevant for susceptibility to neuropsy-
chiatric disorders. Specifically, hemizygosity of NETO1 was shown
to be associated with a autistic-like behaviors in humans [12].
Although unequivocal genome wide evidence (p,10
28) for
association at the NETO1 locus has not been reported, it is of
note that in the recent GWASs of Alzheimer’s disease and
schizophrenia, suggestive association signals were observed
(rs1109070; p=0.000669 [13] and rs9962470; p=0.000154 [14]
in Alzheimer’s disease and schizophrenia, respectively). Moreover,
several weak association signals (P,0.05) within the NETO1 locus
were detected in the first GWAS of schizophrenia conducted in the
Japanese population (JGWAS) [15]. It is of note that in the
JGWAS, genome wide evidence for association was not detected,
and the non-genome wide level of statistical significance should be
interpreted with caution. However due to the relatively small
sample size, type II errors (false negative result) cannot be excluded
– especially in the case of small odds ratios (OR) which are
expected for common SNPs associated with schizophrenia [16].
Based on the aforementioned biological studies, NETO1 can be
seen as a promising candidate gene for schizophrenia. However, to
the best of our knowledge, no genetic association study specifically
designed to evaluate the association between NETO1 and
schizophrenia has been conducted. The goal of the present study
was to evaluate the association between NETO1 and schizophrenia
based on the JGWAS. Additionally, as deficits were found in LTP
and learning and memory in Neto1-null mice [7], we performed a
cognitive function analysis that targeted the relationship between
common SNPs selected based on the JGWAS and cognitive
function assessed by the CPT and the WCST.
Results
In the replication sample set, we did not detect any association
between eight SNPs and schizophrenia after Bonferroni correction
was applied (Table 1). Using the replication sample set, we have
conducted haplotype-wise analysis in order to investigate associ-
ation between haplotypes within the NETO1 locus and schizo-
phrenia. We did not detect evidence for haplotype-wise association
after Bonferroni correction was applied (Table S1). In order to
maximize the power, we performed meta-analysis combining
results from the JGWAS and the replication dataset. In this
analysis we could detect three suggestive association signals
(rs17795324: P=0.028, rs8098760: P=0.017, rs17086492:
P=0.003). In the test of heterogeneity, we detected four SNPs,
which showed significant high heterogeneities (Breslow-Day test;
rs17795324: P=0.04, rs6566674: P=0.01, rs8098624: P=0.003,
rs1109070: P=0.0001) (Table 2). However, we could not detect
any association between these three SNPs (rs17795324, rs8098760
and rs17086492) and CPT and WCST scores (Table S4). We
investigated the association between the NETO1 gene and
schizophrenia stratified by gender. We could detect no association
signals either for males or females in the meta-analysis after
Bonferroni correction (Tables S2 and S3).
Discussion
In this study, we investigated the association between eight
SNPs within NETO1 and schizophrenia in the Japanese popula-
tion. We detected associations between NETO1 and schizophrenia
in the meta-analysis, however, as the JGWAS dataset was included
in the meta-analysis, evidence for association might be overesti-
mated. In order to address this issue we tested the association
between candidate SNPs from our meta-analysis and cognitive
performance measured by the CPT and WCST. This analysis was
of interest for us as Neto1-null mice show deficits in LTP and
learning and memory [7], and if the three SNPs (rs17795324,
rs8098760, rs17086492) were genuinely associated with schizo-
phrenia, then carriers of risk alleles would likely have deficits in
cognitive processing assessed by CPT and WCST [6]. However,
we could not detect any association between these three SNPs
(rs17795324, rs8098760, rs17086492) and the psychological tests
we applied. We also performed meta-analysis (Method S1) of
rs6566674 (the SNP that was included both in our replication
sample set and another Japanese GWAS [17]), however we did not
detect evidence for an association with schizophrenia. These
results suggest that NETO1 is not associated with schizophrenia in
the Japanese population.
We detected four SNPs, which showed heterogeneous associ-
ation (Breslow-Day test; rs17795324: P=0.04, rs6566674:
P=0.01, rs8098624: P=0.003, rs1109070: P=0.0001) in the
meta-analysis. These high heterogeneities may be derived from
flip-flop phenomenon, that is, associations of opposite alleles at the
same biallelic locus with the same disease [18]. Although the flip-
Association Study and Cognitive Analysis of NETO1
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(i.e., genuinely different LD architectures across populations with
different ancestral origins), it may also be an artifact due to
sampling variation that leads to variability in observed LD
patterns.
Several caveats should be considered when interpreting the
results of our study. First, in terms of sample size, the replication
dataset may not have sufficient statistical power to detect
associations between SNPs with low genotype relative risk
(GRR) and schizophrenia. In other words, our sample has
statistical power greater than 0.8 for the detection of association
signals at nominal statistical significance, of the polymorphism
with a minor allele frequency of 0.1, when the GRR is 1.30.
Therefore, the possibility of association between schizophrenia
Figure 1. NETO1-gene centric data. LD: linkage disequilibrium. NETO1 maps to the 18q22-q23 and three alternative splicing variants (mRNA
level) have been observed. Specifically variants 1 and 2 are detected in retina while variant 3 is specific for fetal and adult brain (mRNA level panel).
NETO1 is a transmembrane protein, which has two extracellular CUB domains, a low-density lipoprotein class A (LDLa) domain, a transmembrane
domain and a classical type I PDZ-domain binding motif (protein level panel).
doi:10.1371/journal.pone.0028929.g001
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Furthermore, the JGWAS may not have sufficient power to detect
associations between SNPs with low GRR and schizophrenia.
Therefore, other relevant common variants in the NETO1 region,
which the JGWAS cannot identify, may exist. In addition,
association between NETO1 and schizophrenia may be specific
only for the patients with early onset age. However, as in the
current study, the frequency of the early onset schizophrenia
patients was low (less than 5%). The power to detect such an
association is inadequate. Therefore, the effect of onset age on the
association between NETO1 and schizophrenia remains to be
investigated in further studies.
The second caveat is that our study design was based on the
common disease, common variant hypothesis, based on which we
applied a minor allele frequency threshold (.5%) and selected
eight SNPs for follow-up. In the best case scenario, common
variants detected in GWAS can explain only part of the
heritability in cases of schizophrenia (,30%) [19] and missense
or nonsense mutations on the one side and structural variations
(i.e., copy number variants (CNVs)) on the other side are likely to
contribute to the increased susceptibility [20]. Recently, the
concept of synthetic associations has been suggested, though some
there are some objections [21]. Uncommon or rare genetic
variants can easily create synthetic associations that are credited to
common variants. This possibility requires careful consideration in
the interpretation and follow up of GWAS signals [22].
The third caveat in our association study is that cases and
controls in replication samples were not matched in age. In other
words, although highly unlikely, the controls may develop
schizophrenia at some point in life, as they were significantly
younger than cases.
The fourth caveat is related to the validity of cognitive function
analysis. The premise that NETO1 was associated with cognitive
function in humans had been derived from results of a knock-out
mice study [7]. Neto1-null mice showed impaired spatial learning
measured by the Morris water maze task, the delayed matching-
to-place version of the Morris water maze task and displaced-
object tasks. In the current study, we investigated executive
function (WCST) and vigilance/attention (CPT-IP), however, the
results of these cognitive tests might not represent similar cognitive
dysfunctions that were shown in the Neto1-null mouse study. It may
be useful to examine different domains of cognitive impairment
Table 1. Results of JGWAS (N=1108).
SNP Position
a Minor allele Case
b Control
b p-value
c OR L95
d U95
d
rs9962470 68616086 A 0.03 0.04 0.31 0.79 0.50 1.24
rs17086334 68626752 C 0.10 0.08 0.05 1.34 1.00 1.80
rs17795324 68654033 G 0.27 0.33 0.003 0.76 0.63 0.91
rs6566674 68662791 T 0.20 0.16 0.04 1.26 1.01 1.57
rs8098624 68669199 T 0.30 0.24 0.002 1.35 1.12 1.63
rs8098760 68669970 T 0.11 0.08 0.02 1.42 1.06 1.90
rs17086492 68674050 C 0.14 0.10 0.001 1.52 1.17 1.98
rs1109070 68674559 C 0.21 0.16 0.01 1.35 1.09 1.68
abased on NCBI 36.
bminor allele frequency.
cFisher’s exact test.
dLower (L) and upper (U) 95% confidence intervals.
doi:10.1371/journal.pone.0028929.t001
Table 2. Allele frequencies of the eight SNPs of NETO1.
SNP Position
a Minor allele Replication (N=1882) Meta analysis (N=2990)
Case
b Control
b p-value
c OR L95
d U95
d p-value
c OR L95
d U95
d BDp
e
rs9962470 68616086 A 0.02 0.03 0.24 0.79 0.53 1.18 0.126 0.79 0.59 1.07 0.99
rs17086334 68626752 C 0.08 0.08 0.87 0.98 0.77 1.25 0.289 1.11 0.92 1.33 0.09
rs17795324 68654033 G 0.29 0.30 0.61 0.96 0.84 1.11 0.028 0.88 0.79 0.99 0.04
rs6566674 68662791 T 0.17 0.19 0.12 0.88 0.74 1.04 0.926 1.01 0.88 1.15 0.01
rs8098624 68669199 T 0.27 0.29 0.43 0.94 0.82 1.09 0.213 1.08 0.96 1.21 0.003
rs8098760 68669970 T 0.10 0.08 0.18 1.17 0.93 1.47 0.017 1.24 1.04 1.49 0.26
rs17086492 68674050 C 0.12 0.11 0.22 1.14 0.93 1.39 0.003 1.28 1.09 1.50 0.09
rs1109070 68674559 C 0.16 0.19 0.01 0.78 0.65 0.93 0.718 0.98 0.85 1.12 0.0001
abased on NCBI 36.
bminor allele frequency.
cFisher’s exact test.
dLower (L) and upper (U) 95% confidence intervals.
ep-value of Breslow-Day test.
doi:10.1371/journal.pone.0028929.t002
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cognitive assessment tools.
In conclusion, we were not able to detect evidence for an
association between NETO1 and schizophrenia in the Japanese
population. Common variants within the NETO1 locus may not
increase the genetic risk for schizophrenia in the Japanese
population. Additionally, common variants investigated in the
current study did not affect cognitive performance, as measured by
the CPT and the WCST.
Materials and Methods
Participants
This study was approved by the Ethics Committees of the
Nagoya University Graduate School of Medicine and Fujita
Health University, and written informed consent was obtained
from each participant. Patients were included in the study if they
(1) met DSM-IV criteria for schizophrenia, (2) were physically
healthy and (3) had no mood disorders, substance abuse,
neurodevelopmental disorders, epilepsy or known mental retar-
dation. A general characterization and psychiatric assessment of
subjects is available elsewhere [23]. Controls were selected from
the general population. Control subjects had no history of mental
disorders, based on questionnaire responses from the subjects
themselves during the sample inclusion step, and based on an
unstructured diagnostic interview done by an experienced
psychiatrist during the blood collection step. The JGWAS
sample was comprised of 575 patients with schizophrenia
(43.5614.8 years (mean6s.d.), male 50%) and 564 healthy
controls with no personal or family history of psychiatric illness
(44.0614.4 years (mean6s.d.), male 49.8%). All subjects were
unrelated, living in the central area of the Honshu island of
Japan and self-identified as members of the Japanese population.
Subjects of replication samples consisted of 963 schizophrenic
patients (47.760.5 years (mean6s.d.), male 55.2%) and 919
healthy controls (45.060.5 years (mean6s.d.), male 51.0%). The
JGWAS and replication samples were collected independently at
each university hospital.
Genotyping and data analysis
Based on the JGWAS results we initially selected SNPs with
probability values, p,0.05 and allelic frequencies, MAF.0.05
within the NETO1 locus. Then we identified redundant SNPs
based on the linkage disequilibrium or LD pattern within the
interrogated region. Specifically, if the correlation coefficient
between two loci (r
2) was 0.8 or higher, only one of the two loci
was selected for the association study [24]. The correlation
coefficient between two loci (r
2) was calculated using Haploview
v.4.1 based on the HapMap database (release no. 24, population:
Japanese in Tokyo). Finally, we selected seven nonredundant SNPs
within the NETO1 locus. Moreover, one common polymorphism
(rs9962470), which showed a low p-value (p=0.000154) in a
previous GWA study [14], was included for genotyping. All eight
SNPs are intronic polymorphisms. DNA was extracted from
peripheral blood according to a standard protocol [23]. Genotyp-
ing was performed using a fluorescence-based allelic discrimina-
tion assay (Taqman, Applied Biosystems, Foster City, CA, USA).
Power was calculated according to the methods of Skol et al. [25].
To exclude low-quality DNA samples or genotyping probes,
data sets were filtered on the basis of SNP genotype call rate (more
than 90%) or checked deviation from Hardy-Weinberg equilibri-
um (HWE) in the control sample. Subjects whose percentage of
missing genotypes was .30% or who had evidence of possible
DNA contamination were excluded from subsequent analyses.
To reduce the total number of tests, eight associated markers
were selected based on the JGWAS results. Next, conditional on
the findings of the JGWAS, which used a less stringent nominal
level, a meta-analysis was done involving the confirmation sample
using the replication data and data from the JGWAS. In the
replication sample, Fisher’s exact test was used to compare allele
frequencies between patients and control subjects. The signifi-
cance level was set at p,0.05. In the replication sample set, log
likelihood ratio tests for assessing haplotype-wise association
between schizophrenia and a combination of tagging SNPs was
performed using UNPHASED software v3.04. The rare haplotype
frequency threshold was set at 5% [26]. In this meta-analysis, p-
values were generated by a Cochran–Mantel–Haenszel stratified
analysis, and the Breslow–Day test was performed for evaluations
of heterogeneous associations as implemented in gPLINK v.2.050
[27].
Neurocognitive assessment
1. CPT. We used the Continuous Performance Test–Identical
Pairs Version Release 4.0 (NewCPT.exe, Copyright 1982–2004 by
Barbara A. Cornblatt, All Rights Reserved). The size of PC
monitor used for the test was 10.4 inches as each letter was at least
2.261.5 cm [28]. Stimuli were flashed on the screen at a constant
rate of 1 per second, with a stimulus ‘‘on’’ time of 50 ms. Stimuli
were four-digit numbers and were presented 150 times. In each
150-trial condition, 30 of the trials (20%) were target trials and
required a response. Target trials were those on which the second
of a pair of two identical stimuli appeared [28]. The outcome
measure was a mean, d9.
2. WCST. The WCST [29] mainly assesses executive function
including cognitive flexibility in response to feedback. We used a
modified and computerized version of the test: Wisconsin Card
Sorting Test (Keio Version) (KWCST) [30]. The outcome
measures were numbers of categories achieved (CA), total errors
(TE), and perseverative errors of Milner (PEM) and Nelson types
(PEN) in the first trial. We selected outcomes in the WCST,
following a prior study, which used KWCST as a measure of
cognitive function [31].
(1) CA: This is the number of categories for which six
consecutive correct responses are achieved (eight is the maximum
number of categories which can be achieved), and is the sum
measure of the level of conceptual shifts in the KWCST.
(2) PEN: This is the number of incorrect responses in the same
category as the immediately preceding incorrect response
(maximum of 47 perseverative errors) [32].
(3) PEM: This is the number of incorrect responses in the same
category as the immediately preceding correct response after the
category changes.
(4) TE: This is the total number of incorrect responses [33].
3. Clinical information. Chlorpromazine (CPZ) equivalent
doses were calculated based on the report by Inada [34,35]. The
Positive and Negative Symptom Scale (PANSS) was used to
evaluate patients [36].
4. Analysis of cognitive performance. From the sample
used in the current study, we made a subset of randomly selected
participants older than 18 years of age for analysis of cognitive
performance. Cognitive data analysis was done for the participants
who completed both WCST and CPT-IP. We checked the effect
of three SNPs on cognitive performance measured by the
Continuous Performance Test and the Wisconsin Card Sorting
Test (107 schizophrenic patients, 104 Healthy controls). IBM
SPSS statistical software, version 19 was used for all analyses. We
compared age, education, CPZ equivalent doses, age at onset,
duration of illness, positive scale, negative scale and General
Association Study and Cognitive Analysis of NETO1
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28929Psychopathology Scale between schizophrenia cases and control
subjects using a two-tailed t-test and Welch’s t-test. We compared
sex between case and control groups using Fisher’s exact test.
Next, we compared d9 in the CPT and CA, PEM, PEN, TE in the
WCST between the case and control groups using a two-tailed t-
test and Welch’s test (Table S4).
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